Context: Malignant pheochromocytoma (PHEO) and paraganglioma (PGL) are rare and knowledge of the natural history is limited.
PPGL is seen as a part of multiple endocrine neoplasia (MEN) type 2, von Hippel-Lindau (VHL) disease, and neurofibromatosis type 1 (NF1). Hereditary PPGL is mainly seen with mutations in succinate dehydrogenase (SDH) subunits (5, 6) . Less common germline mutations associated with PPGL include mutations in transmembrane protein 127 (TMEM127), myc-associated factor X genes, somatic gain-of-function mutations in the gene encoding hypoxia-inducible factor 2a, and pathogenic germline mutations in the FH gene encoding fumarate hydratase (7) (8) (9) (10) .
According to the World Health Organization, the diagnosis of malignant PPGL requires evidence of metastases at nonchromaffin sites distant from the primary tumor, such as lymph nodes, bones, liver, lung, brain, and others (11) . Malignant disease has been reported in 2% to 13% of patients with PHEO and 2.4% to 50% with PGL (12) (13) (14) . At least 11% of all patients with PPGL and up 31% of patients with PPGL in the setting of predisposing genetic mutation present with synchronous metastatic disease at the time of primary tumor diagnosis (15, 16) . Predicting malignant disease in patients presenting with primary tumor without metastases is difficult, and there are no reliable clinical, molecular, histopathological, or biochemical markers of malignant potential. Mitotic activity, cellular atypia, or vascular invasion do not reliably predict malignant predisposition of these tumors. Moreover, the extent of local invasion to adjacent tissues does not necessarily indicate higher risk toward development of metastases (4) .
Owing to the rarity of PPGL in general, and metastatic disease especially, current evidence on the natural history of malignant PPGL is scarce. Limited data exist with regard to clinical outcomes of patients with malignant disease; most reports are based on small, highly selected cohorts of patients. The objectives of the present study were to assess overall and disease-specific survival rates of patients with malignant PPGL. We also aimed to describe baseline characteristics and outcomes of patients with malignant PPGL and to identify prognostic factors influencing the course of the disease.
Subjects and Methods

Subjects
To examine the predictive features associated with shorter overall and disease-specific survival, we retrospectively reviewed a consecutive cohort of patients with malignant PPGL evaluated at the Mayo Clinic (Rochester) between 1 January 1960 and 30 September 2016. The study was approved by the Institutional Review Board of the Mayo Clinic. The Mayo Clinic PPGL database was reviewed to identify patients with malignant PPGL. Of 3280 patients, 272 (8.3%) had malignant disease. Diagnosis was confirmed by reviewing clinical, histopathological, and biochemical data. PGL was categorized according to the location of the primary tumor. Patients with both PHEO and PGL were included in the PGL group. Malignant disease was defined in accordance with the 2004 World Health Organization criteria (17) . Synchronous metastatic disease was defined as the presence of distant metastases at the time or within 3 months of the primary tumor diagnosis. Patients who developed metastatic disease $3 months after the diagnosis of the primary tumor were defined to have metachronous metastases. Patients were characterized to have a genetic mutation predisposing to PPGL if they had a documented genetic testing for major PPGL susceptibility genes, familial history of genetic mutation, or presence of at least two National Institutes of Health criteria for diagnosing NF1 syndrome.
All PPGL tumors were defined as functional when urine or plasma-fractionated catecholamines or fractionated or total metanephrines were elevated above the upper limit of respective reference ranges. The reference intervals for plasma concentrations were established at the Mayo Clinic (18) . The tumors were considered nonfunctional when the levels of plasma or urine metanephrines/catecholamines remained within the reference ranges. Tumors hypersecreting primarily epinephrine/ metanephrine or norepinephrine/normetanephrine were termed adrenergic and noradrenergic, respectively. We separately evaluated for dopamine hypersecretion in all tumors and termed them dopaminergic. To investigate whether the time period of diagnosis played a role in baseline characteristics and outcomes of patients with malignant PPGL, we analyzed the variables based on year of diagnosis using the following arbitrary time intervals: 1960 to 1990 and 1991 to 2016. Additionally, for more detailed evaluation of prognostic factors for disease progression, we identified the patients with at least 5 years of follow-up from the primary tumor diagnosis, unless preceded by death due to malignant PPGL, and divided the cohort into two groups: patients with rapidly progressive disease who died of malignant PPGL within 5 years of the primary tumor diagnosis, and patients with indolent disease with at least 5-year disease survival. Patients with ,5 years of followup, or those who died of other causes within 5 years of primary tumor diagnosis, were excluded from this analysis.
Data analysis
Descriptive statistics were used to provide a summary of the data. Categorical data were given as absolute and relative frequencies (percentages). Continuous data were presented as median, minimum to maximum range. To compare medians between two independent groups, we used the nonparametric Wilcoxon rank sum test. In patients with at least 5 years of follow-up after primary diagnosis, logistic regression models were used to estimate association of risk factors of dying within 5 years. Because there were 29 deaths in the rapidly progressive group, a multivariate logistic regression model was fit using three predictors, based on 10 events per predictor rule. The variables chosen to be in the multivariate model were based on those reported in prior studies. All tests were two-sided, and P values , 0.05 were considered statistically significant. All statistical analyses were conducted using JMP version 10 (SAS Institute, Cary, NC). 36%), PGL (n = 159, 58%), or both (n = 16, 6%) ( Table 1 ). Patients presented with the primary tumor at the median age of 39 years (range, 7 to 83 years).
Although most cases of PPGL were apparently sporadic (191 patients, 70%), in 81 (30%) patients PPGL occurred in the context of a hereditary syndrome: 42 (15.4%) patients with SDHB mutation; 7 (2.6%) with SDHD mutation; 4 (1.5%) with NF1; 3 (1.1%) with VHL disease; 3 (1.1%) with MEN type 1 (MEN1); 3 (1.1%) with MEN type 2A; 2 (0.7%) with SDHC; 1 (0.4%) with Carney triad; and 1 (0.4%) with a TMEM127 mutation. Fifteen patients (5.5%) were diagnosed with familial PPGL based on family history (Table 1) .
PPGL was preceded by adrenergic symptoms (e.g., spells, hypertension, headache, palpitations) in 137 (50%) patients, by tumor-related mass effect (lump, pain, compression of surrounding structures) in 70 (26%) patients, or discovered incidentally on imaging in 65 (24%) patients. Median size of the primary tumor at the time of the initial diagnosis of PPGL was 7.0 cm (range, 0.9 to 26.0 cm). Of 248 patients with sufficient biochemical testing data, catecholamine hypersecretion was observed in 197 (79%) patients (Table 2) .
Ninety-six (35%) patients presented with synchronous metastases, whereas 176 (65%) patients developed metachronous metastases at a median of 5.5 years (range, 0.3 to 53.4 years) after the primary tumor diagnosis ( Table 1 ). The most common locations of metastases were bone (n = 161, 59.1%), lymph nodes (n = 127, 46.7%), liver (n = 99, 36.4%), lungs/thorax (n = 103, 37.9%), and abdomen/pelvis (n = 86, 31.6%).
Surgery was the most common treatment of primary tumors (n = 243, 89.3%). Twenty-eight (10.3%) patients were determined to have unresectable tumors; one (0.4%) patient was a poor surgical candidate due to comorbidities. Out of 164 patients, 159 (97%) patients underwent additional surgical resection (for reoperation of primary tumors or metastasectomy). Palliative radiotherapy was performed in 128 (47%) patients. Ninety-five (35%) patients received chemotherapy and targeted molecular therapy (cyclophosphamide, vincristine, I-metaiodobenzylguanidine treatment, 16 (5.8%) had embolization procedures, 13 (4.7%) had stereotactic radiotherapy, 11 (4%) had cryoablation, and 2 (0.7%) had percutaneous ethanol injection.
Patients were followed for a median of 8.2 years (range, 0.01 to 54.1 years) from the initial diagnosis and for a median of 4.0 years (range, 0.01 to 40 years) from the time of metastatic spread. Among patients with ,1 year of follow-up (n = 15, 6%), 53% died of disease, 7% died of other causes, and 40% were alive at last followup. Among patients with 1 to 5 years of follow-up (n = 69, 25%), 31% died of disease, 7% died of other causes, and 62% were alive at last follow-up. Of those with 5 to 10 years of follow-up (n = 66, 24%), 26% died of disease, 10% died of other causes, and 64% were alive with disease. One hundred twenty-two patients (45%) had .10 years of follow-up: 22% died of disease, 12% died of other causes, and 66% were alive with disease at last follow-up (Fig. 1) .
Among patients alive at last follow-up, median duration of follow-up was 8.8 years (range, 0.01 to 54.1 years) and 4.7 years (range, 0 to 38.0 years) from the initial tumor diagnosis and metastases, respectively. At the conclusion of the study, 154 (57%) patients were alive with disease and 18 (6%) patients had disease remission.
One hundred (37%) patients died during follow-up; 73 (27%) patients died of malignant PPGL and 27 (10%) patients died of causes unrelated to PPGL. In 73 (27%) patients who died of malignant PPGL, the median survival was 6 years (range, 0.01 to 41 years) and 3 years (range, 0.01 to 17 years) from primary diagnosis and development of metastasis, respectively ( Table 1) .
Year of diagnosis
Of 272 patients, 97 (54.6% women) were diagnosed between 1960 and 1990, and 175 patients (48.6% women) were diagnosed between 1991 and 2016. Among those diagnosed before 1990 vs after 1990, more patients presented with adrenergic symptoms (n = 61, 62.9% vs n = 76, 43.4%; P = 0.002), a similar proportion presented with mass effect symptoms (n = 24, 24.7% vs n = 46, 26.3%; P = 0.78), and fewer were diagnosed incidentally (n = 12, 12.4% vs n = 53, 30.3%; P = 0.0006) (Supplemental Table1).
There was no between-group differences in tumor size (P = 0.57), rate of surgical resection of primary tumor (P = 0.89), functional PPGL (P = 0.22), or proportion of patients with rapid disease progression (P = 0.34) (Supplemental Table 1 ).
Primary tumor type
Patients with malignant PHEO (n = 97, 36%) and PGL (n = 175, 64%) had similar sex distribution (P = 0.58).
Compared https://academic.oup.com/jcemP = 0.013), and more likely to have multifocal disease (33% vs 8%; P , 0.0001) (Supplemental Table 2 ). Patients with malignant PGL had more bone (67% vs 45%; P = 0.0006) and lymph node (53% vs 35%; P = 0.004) metastases compared with PHEO, whereas liver metastases were more common in patients with PHEO (49% vs 30%; P = 0.002). There were no differences in the rates of lung/thoracic, abdominal/pelvic, or brain metastases between groups (P . 0.05). Importantly, there were no differences between rapidly progressive and indolent metastatic disease among PHEO and PGL (P = 0.14) and disease-specific mortality (P = 0.07) (Supplemental Table 2 ).
Risk of rapid disease progression
Among patients with sufficient follow-up, 29 patients had rapid disease progression (,5 year survival from the time of primary tumor diagnosis) and 188 patients had indolent disease (alive for at least 5 years from the time of diagnosis) ( Table 3 ). Univariate analysis demonstrated that rapid disease progression was associated with male sex (n = 20, 69% vs n = 84, 45%; P = 0.014), older age at primary tumor diagnosis [50 years (range, 7 to 70 years) vs 36 years (range, 9 to 83 years); P = 0.0011], synchronous metastases (n = 22, 76% vs n = 40, 21%; P , 0.0001), larger primary tumor size [10.0 cm (range, 1.0 to 19.1 cm) vs 6.4 cm (range, 0.9 to 22.0 cm); P = 0.0039], elevated dopamine levels (n = 10, 71% vs n = 49, 39%; P = 0.0195), and not undergoing surgical resection of primary tumor (19, 66% vs 181, 96%; P , 0.0001) ( Table 4) . None of the patients with skull base and neck PGL had rapid disease progression. Additionally, patients with rapidly progressive disease more frequently developed lung/thoracic metastases (n = 17, 59% vs n = 67, 36%; P = 0.0197). There was a similar distribution among other metastatic sites between the groups.
There were no between-group differences in the year of primary tumor diagnosis (1995 vs 1991), type of primary tumor (48% vs 34% PHEOs, 52% vs 66% PGL), age at diagnosis of metastases (50 vs 43 years), or presence of SDHB mutation (10% vs 17%) ( Table 3) .
Fewer patients in the rapidly progressive group underwent reoperation of primary tumors or metastasectomy (n = 10, 35% vs n = 138, 73%; P , 0.0001). Patients with rapidly progressive disease more commonly received chemotherapy (n = 17, 59% vs n = 59, 31%; P = 0.0052).
Multivariate analysis showed that independent factors associated with rapid disease progression and mortality in patients with malignant PPGL included: older age at primary diagnosis [odds ratio (OR) = 1.04; 95% confidence interval (CI), 1.01 to 1.08; P = 0.0047, for 1 year age difference], larger tumor size (OR = 1.12; 95% CI, 1.009 to 1.25; P = 0.034, for each 1 cm increase in tumor size), and synchronous metastases (OR = 10.24, 95% CI 3.76 to 31.18; P , 0.0001) ( Table 4) .
Median overall survival was 24.6 years for patients with malignant PPGL (Fig. 2) . The 5-year overall survival rate was 85.4% (79.2% for PHEO, 88.9% for PGL), 10-year overall survival rate was 72.5% (64.2% for PHEO, 77.3% for PGL), and 15-year overall survival was 65.4%. Median disease-specific survival was 33.7 years. Disease-specific survival rate was 88.1% at 5 years, 77.9% at 10 years, and 71.8% at 15 years. Overall and disease-specific survival rates were similar for patients with metastatic PHEO and PGL (P = 0.22 and P = 0.87).
Discussion
We found that the clinical behavior of malignant PPGL is remarkably variable. For example, whereas in some patients discovery of metastases precedes discovery of the primary tumor, others develop metastases .50 years after the initial diagnosis.
We observed a median overall survival of 24.6 years and a median disease-specific survival of 33.7 years. Previous reports on the clinical course of metastatic PPGL have been widely inconsistent, with the 5-year survival rates ranging from 12% to 84% (4, (19) (20) (21) (22) (23) . Without treatment, the 5-year survival rate has been reported to be generally ,50% (24) . In contrast, our study showed that overall and disease-specific 5-year survival rates were 85.4% and 88.2%, and 10-year overall and diseasespecific survival rates were 72.5% and 77.9%, respectively. These results indicate that a substantial number of patients have an excellent prognosis despite having malignant PPGL. Similar to previous reports, we found that the course of the disease can be highly variable with some patients living .50 years after diagnosis (25, 26).
We found that male sex, older age at primary tumor diagnosis, dopamine hypersecretion, synchronous metastases, larger primary tumor size, and not undergoing surgical resection of the primary tumor were associated with an aggressive disease course and higher mortality risk. On the multivariate analysis, older age at primary tumor diagnosis, larger primary tumor size, and presence of synchronous metastases remained significant predictors of rapid disease progression and death. Comparable to our findings, others have previously reported that male sex (20) , older age at the primary tumor diagnosis (age $ 76 years) (20, 27) , and failure to undergo surgical resection of the primary tumor (20) (21) (22) were associated with shorter survival (20) .
In our study, larger primary tumor size was associated with rapid disease progression and higher mortality risk.
Similarly, larger tumor size (generally .4.5 to 5 cm) has been reported as a strong predictor of persistent or recurrent disease and mortality in several other studies (4, 20, 24, 28, 29) . In one study, primary tumor size $ 6 cm was found to be an important independent risk factor for metastatic disease (30) , and tumor size was significantly associated with worse overall survival after adjusting for age, sex, and tumor location (23) . Another study reported that in SDHB-related PPGL the size of the primary tumor predicts development of metastatic disease and also affects patient survival (31) .
We observed an association between dopamine hypersecretion and more aggressive malignant disease. High plasma and urinary levels of dihydroxyphenylalanine and dopamine, the immediate precursors of norepinephrine, are biochemical markers that may characterize malignant PPGL (24, 32, 33) . These markers suggest a dedifferentiated state suggestive of malignant potential; however, they do not accurately discriminate benign from malignant disease.
Similar to our results, the timing of metastasis was an important determinant of prognosis in other studies (4, 20, 23) . Presence of synchronous metastases has been associated with shorter survival, whereas onset of metastasis .6 months after the initial diagnosis or resection of the primary tumor had longer overall survival durations than in patients with synchronous metastasis.
In our study, patients with malignant skull base and neck PGL had indolent courses of disease with longer survival (overall 5-year survival rate was 85.4% and 5-year disease-specific survival rate was 88.2%). Among patients with sufficient follow-up, none with malignant skull base and neck PGL died of disease within 5 years of primary diagnosis. Similarly, others showed that 5-year overall survival was 88.1% for surgery alone and 66.5% for adjuvant radiation (P = 0.23) for 86 patients with malignant skull base and neck PGL (34) . In contrast, another study that evaluated prognosis of 59 patients with skull base and neck PGL metastatic to regional lymph nodes and distant sites reported a much shorter 5-year relative survival rate of 59.5% (21) .
Interestingly, we did not find that primary tumor type, multifocal PPGL, location of primary tumor (except skull base and neck), functional biochemical status, or presence of SDHB mutation played a significant role in the progression of malignant disease. Germline mutations of the SDHB gene are considered one of the most important risk factors for developing metastatic PPGL, with rates up to 50% to 90% in some studies (3, 23, (35) (36) (37) . Previous studies have also reported that in cases of malignant PPGL, SDHB mutation was identified in 5% to 10% of patients (38) . In contrast to our findings, these mutations have been associated with more aggressive tumor behavior than other PPGL types (3, 4, 23, (35) (36) (37) . Patients with malignant SDHB-positive PPGL were reported to have a shorter overall survival (5-year survival probability 0.36, relative risk 2.6; P = 0.019) compared with patients with malignant PPGL not associated with SDHB mutations (35) . Another retrospective review found that adult patients with SDHB mutations had statistically worse survival than did those with apparently sporadic disease (39) .
We found no difference in survival rates among patients with malignant PHEO and PGL. In contrast to our findings, others have reported that patients with PHEO had longer overall survival (73.3% vs 54.0%; P = 0.001) compared with PGL, although disease-specific survival rates were similar (80.5% vs 73.5%, respectively; P = 0.118) (20) .
Our study included a large number of patients with malignant PPGL. Given the retrospective design of this study, follow-up of patients varied based on clinical and patient decisions. Nevertheless, the design of the study allowed for a long follow-up of patients, otherwise not feasible in a prospective study. Most patients with a rare malignant disease are followed at tertiary centers, and thus it is likely that our cohort is representative. It is possible that patients with more aggressive disease were more likely to be referred and followed at our institution. Additionally, differences between rapidly progressive and indolent cohort may in part be due to delayed presentation of patients with the rapidly progressive disease. The reasons for better prognosis in our cohort in comparison with others could be explained by referral bias, longer duration of follow-up than most other studies, and inclusion of a nonselective cohort.
Conclusion
In conclusion, patients with malignant PPGL have a markedly variable course of the disease and longer overall and disease-specific survival than previously reported. Although death can occur within a year of diagnosis, metastatic disease can be stable for .40 years. Detection of metastases can occur prior to the detection of primary tumors, but metastatic spread can also be discovered .50 years after the primary diagnosis. Therefore, lifelong follow-up of patients with PPGL is indicated. Larger tumor size, older age at diagnosis, and failure to undergo surgery could be indicators of delayed diagnosis and may be avoidable in some patients. Additionally, these factors, along with synchronous metastases and dopamine hypersecretion, could represent intrinsically more aggressive disease. Thus, a multidisciplinary and individualized approach to treatment of patients with metastatic PPGL is warranted.
